The Chemours Company (NYSE:CC) Holdings Raised by Bank of Montreal Can

Bank of Montreal Can increased its stake in The Chemours Company (NYSE:CC - Free Report) by 1,496.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 953,240 shares of the specialty chemicals company's stock after acquiring an additional 893,530 shares during the period. Bank of Montreal Can owned approximately 0.64% of Chemours worth $16,110,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Strategic Financial Concepts LLC purchased a new stake in shares of Chemours during the 4th quarter worth about $357,000. Entropy Technologies LP purchased a new stake in Chemours during the fourth quarter worth approximately $266,000. Sei Investments Co. increased its position in shares of Chemours by 779.5% in the fourth quarter. Sei Investments Co. now owns 174,555 shares of the specialty chemicals company's stock worth $2,950,000 after acquiring an additional 154,709 shares in the last quarter. Twelve Points Wealth Management LLC raised its stake in shares of Chemours by 42.8% in the 4th quarter. Twelve Points Wealth Management LLC now owns 78,325 shares of the specialty chemicals company's stock valued at $1,324,000 after acquiring an additional 23,490 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Chemours by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 2,491,748 shares of the specialty chemicals company's stock valued at $50,646,000 after acquiring an additional 28,803 shares in the last quarter. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Chemours Stock Down 3.4 %

CC stock traded down $0.40 during midday trading on Tuesday, hitting $11.13. 1,744,948 shares of the company's stock were exchanged, compared to its average volume of 1,825,919. The firm has a 50 day moving average price of $14.25 and a 200-day moving average price of $17.49. The Chemours Company has a 12-month low of $9.33 and a 12-month high of $29.21. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of 19.52 and a beta of 1.84. The company has a current ratio of 1.68, a quick ratio of 0.92 and a debt-to-equity ratio of 6.70.

Remove Ads

Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings results on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.01. Chemours had a net margin of 1.51% and a return on equity of 26.54%. The business had revenue of $1.36 billion during the quarter, compared to analyst estimates of $1.37 billion. On average, analysts anticipate that The Chemours Company will post 2.03 EPS for the current year.

Chemours Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, March 14th. Stockholders of record on Friday, February 28th were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Friday, February 28th. This represents a $1.00 annualized dividend and a dividend yield of 8.99%. Chemours's payout ratio is 175.44%.

Analyst Ratings Changes

CC has been the subject of several recent research reports. Barclays lowered their price target on Chemours from $19.00 to $16.00 and set an "equal weight" rating for the company in a report on Tuesday, April 1st. Morgan Stanley lowered their target price on Chemours from $25.00 to $22.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Mizuho set a $15.00 target price on Chemours in a report on Tuesday. Truist Financial decreased their price target on Chemours from $27.00 to $22.00 and set a "buy" rating for the company in a report on Monday. Finally, The Goldman Sachs Group lowered their price objective on shares of Chemours from $24.00 to $21.00 and set a "neutral" rating for the company in a research report on Tuesday, January 7th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Chemours has a consensus rating of "Moderate Buy" and an average target price of $21.56.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.